Daily Roundup | Enspryng Approved for Thyroid Eye Disease as Home Injection & Omeros Refused Again by EU Panel

<p>Friday, October 16 edition.</p><p><br></p><p>Roche’s Enspryng wins FDA approval for thyroid eye disease as a home injection, while Omeros faces another negative European opinion for narsoplimab and plans to end compassionate use there. Alex Mercer and Maya Patel unpack the patient, evidence and commercial implications.</p><p><br></p><p>Also covered: Talvey’s proposed earlier-line use in Europe; Arrowhead’s early ARO-MAPT tau data in healthy volunteers; Foundayo’s European committee recommendations; RYZUMVI’s presbyopia approval; China’s draft drug-technology export controls; and Labcorp’s agreement to acquire select BioReference assets.</p><p><br></p><p>Recorded for Friday, October 16; released October 17 after a freshness check.</p>